abrdn plc cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 1.3% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,023 shares of the biopharmaceutical company’s stock after selling 144 shares during the period. abrdn plc’s holdings in Alnylam Pharmaceuticals were worth $1,806,000 as of its most recent filing with the SEC.
Several other large investors have also recently bought and sold shares of ALNY. Norges Bank acquired a new position in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $215,229,000. Handelsbanken Fonder AB raised its stake in Alnylam Pharmaceuticals by 834.3% in the fourth quarter. Handelsbanken Fonder AB now owns 187,800 shares of the biopharmaceutical company’s stock valued at $31,847,000 after buying an additional 167,700 shares during the period. TD Asset Management Inc. raised its stake in Alnylam Pharmaceuticals by 68.9% in the fourth quarter. TD Asset Management Inc. now owns 396,473 shares of the biopharmaceutical company’s stock valued at $67,234,000 after buying an additional 161,789 shares during the period. Adage Capital Partners GP L.L.C. bought a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $22,435,000. Finally, HighTower Advisors LLC raised its stake in Alnylam Pharmaceuticals by 1,853.5% in the fourth quarter. HighTower Advisors LLC now owns 129,653 shares of the biopharmaceutical company’s stock valued at $22,011,000 after buying an additional 123,016 shares during the period. 92.39% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several research firms have issued reports on ALNY. Oppenheimer restated an “outperform” rating and issued a $205.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 6th. SVB Leerink lifted their price target on Alnylam Pharmaceuticals from $96.00 to $98.00 and gave the stock a “market perform” rating in a report on Wednesday, June 15th. Needham & Company LLC initiated coverage on Alnylam Pharmaceuticals in a report on Thursday, June 16th. They set a “buy” rating and a $205.00 price target for the company. Guggenheim cut Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, June 27th. Finally, William Blair initiated coverage on Alnylam Pharmaceuticals in a report on Tuesday, June 7th. They set an “outperform” rating for the company. Six research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $212.18.
Insider Buying and Selling
Alnylam Pharmaceuticals Trading Down 1.5 %
Shares of ALNY opened at $139.95 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $117.58 and a 52-week high of $212.00. The business’s fifty day moving average is $139.43 and its 200-day moving average is $146.48. The company has a debt-to-equity ratio of 3.85, a quick ratio of 3.62 and a current ratio of 3.76. The firm has a market cap of $16.91 billion, a price-to-earnings ratio of -17.13 and a beta of 0.74.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.62) by ($0.67). Alnylam Pharmaceuticals had a negative net margin of 110.91% and a negative return on equity of 204.18%. The business had revenue of $224.80 million during the quarter, compared to the consensus estimate of $256.06 million. During the same quarter in the previous year, the business posted ($1.61) EPS. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -7.06 EPS for the current fiscal year.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
- Get a free copy of the StockNews.com research report on Alnylam Pharmaceuticals (ALNY)
- MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
- The Colgate-Palmolive Growth Outlook Brightens
- Deep Value High Yield Newell Brands Is Ready To Bottom
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.